RobertRisingerMD

Psychiatry • New Haven, CT

Child & Adolescent Psychiatry, Neuropsychiatry, Psychopharmacology, Clinical Pharmacology

Physician

Join to view full profile

Dr. Risinger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Risinger's full profile

Already have an account?

Office
BioXcel Therapeutics
555 Long Wharf Drive
New Haven, CT 06511

Summary

Dr. Robert Risinger is a psychiatrist in New Haven, CT. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice 29 years. He specializes in child & adolescent psychiatry, neuropsychiatry, psychopharmacology, and clinical pharmacology and is experienced in learning disorders and attention-deficit/hyperactivity disorder.

Education & Training

National Institutes of Health Clinical CenterResidency, Psychiatry, 1991 - 1994
Emory University School of MedicineResidency, Psychiatry, 1988 - 1991
University of Pittsburgh School of MedicineClass of 1988

Certifications & Licensure

WI State Medical License 1997 - 2025

Clinical Trials

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia Start of enrollment: 2015 Dec 01
Completed
Phase 4
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder Start of enrollment: 2015 Dec 01
Completed
Phase 1
Sequential Therapy for the Treatment of Severe Bipolar Depression. Start of enrollment: 2018 Jan 15
Completed
Phase 2
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation Start of enrollment: 2022 May 12
Completed
Phase 2, Phase 3
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation Start of enrollment: 2019 Dec 01
Active, not recruiting
Phase 3
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression Start of enrollment: 2019 Jun 25
Active, not recruiting
Phase 3
NRX101 Glx Biomarker Validation Study Start of enrollment: 2018 Nov 01
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

6 citations
Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.
Jermaine D Jones, Lavanya Rajachandran, Frank Yocca, Robert Risinger, Michael De Vivo
The American Journal of Drug and Alcohol Abuse. 2023-01-02
Correction to: Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed...
Leslie Citrome, Robert Risinger, Lavanya Rajachandran, Heather Robison
Advances in Therapy. 2023-01-01
11 citations
Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.
Leslie Citrome, Sheldon H Preskorn, John Lauriello, John H Krystal, Rishi Kakar
The Journal of Clinical Psychiatry. 2022-10-03

Press Mentions

BXCL501 Seen to Ease Alzheimer’s Agitation in Phase 3 TrialJuly 2nd, 2023
BioXcel Therapeutics Announces Positive Topline Results from TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related AgitationJune 30th, 2023
BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for at-Home Use in Acute Treatment of Agitation in Bipolar Disorders or SchizophreniaMay 25th, 2023
Join now to see all